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Treating to target in psoriatic arthritis:
assessing real-world outcomes and
optimising therapeutic strategy for adults
with psoriatic arthritis—study protocol for
the MONITOR-PsA study, a trials within
cohorts study design
Ines Rombach1, William Tillett2,3, Deepak Jadon4, Laura Tucker5, Marion Watson5, Anne Francis5, Yvonne Sinomati5,
Lucy Eldridge1, Melina Dritsaki1, Susan J. Dutton1, Hussein Al-Mossawi5, Nicola Gullick6, Ben Thompson7 and
Laura C. Coates5*
Abstract
Background: The Tight Control of psoriatic arthritis (TICOPA) trial confirmed improved clinical outcomes with a
treat to target (T2T) strategy in psoriatic arthritis (PsA). This consisted of 4-weekly review and escalation of ‘step up’
therapy (single disease modifying therapy (DMARD), combination DMARDs and then biologics) based on remission
criteria. Based on this, a T2T approach is supported by European PsA treatment recommendations. However, it is
not commonly implemented in routine care primarily due to feasibility and cost concerns. In the TICOPA trial, the
same treatment regime was used for all participants regardless of their disease profile. Despite the recognition of
PsA as a highly heterogeneous condition, no studies have tailored which drugs are used depending on disease
severity. The cohort will establish real world outcomes for the T2T approach in PsA and also form the basis of a
trials within cohorts (TWiCs) design to test alternative therapeutic approaches within embedded clinical trials
providing an evidence base for treatment strategy in PsA.
Methods: The Multicentre Observational Initiative in Treat to target Outcomes in Psoriatic Arthritis (MONITOR-PsA)
cohort will apply a T2T approach within routine care. It will recruit newly diagnosed adult patients with PsA starting
systemic therapies. The cohort is observational allowing routine therapeutic care within NHS clinics but a T2T
approach will be supported when monitoring treatment within the cohort. Eligible participants will be adults (≥18
years) with active PsA with ≥ 1 tender or swollen joints or enthesis who have not previously had treatment with
DMARDs for articular disease.
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Discussion: This study is the first TWiC designed to support a fully powered randomised drug trial. The results from
the observational cohort will be compared with those observed in the TICOPA trial investigating the clinical
effectiveness and health care costs of the pragmatic T2T approach. Nested trials will provide definitive RCT evidence
establishing the optimal management of PsA within the T2T approach. The TWiCs design allows robust
generalizability to routine healthcare, avoids disappointment bias, aids recruitment and in future will allow
assessment of longer-term outcomes.
Trial registration: ClinicalTrials.gov NCT03531073. Retrospectively registered on 21 May 2018.
Keywords: Psoriatic arthritis, Treat-to-target, TWiCs, Trials within cohorts, Cohort multiple RCT or cmRCT
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Introduction
Background and rationale {6a}
Psoriatic arthritis (PsA) is an inflammatory arthritis
estimated to occur in 15% of people with psoriasis [1]
affecting around 150,000 people in the UK [2]. Two
thirds of people with PsA suffer progressive joint
damage with associated disability [3, 4]. People with PsA
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have similar functional and quality of life impairment to
rheumatoid arthritis (RA) [5].
The TICOPA trial was the first randomised controlled
trial to demonstrate improved clinical and patient-
reported outcomes with a ‘treat to target’ approach in
PsA and consisted of 4-weekly reviews and escalation of
treatment aiming for the minimal disease activity
(MDA) criteria [6]. This led to the 2015 European
League Against Rheumatism (EULAR) Treatment rec-
ommendations for PsA incorporating as its first recom-
mendation that ‘treatment should be aimed at reaching
the target of remission or, alternatively, minimal/low dis-
ease activity, by regular monitoring and appropriate ad-
justment of therapy’ [7]. However, despite the evidence
[6] and the EULAR recommendations supporting ‘treat
to target’ in PsA [7], it has not been widely implemented
[8]. In clinical practice, the 4-weekly review used in the
TICOPA trial is not affordable or feasible and is too in-
tensive for both patients starting new therapies or those
stable in MDA. We therefore aim to establish a prag-
matic feasible ‘treat to target’ approach in a real-life
clinic population which can provide similar clinical and
health-related quality of life outcomes to those seen in
TICOPA at a lower cost. Dissemination of these results
will aid translation of ‘treat to target’ into clinical
practice.
Within a treat to target (T2T) approach, there is little
evidence base to support the choice and sequencing of
disease-modifying anti-rheumatic drugs (DMARDs), ei-
ther conventional (csDMARD) or biologic (bDMARD).
Despite the recognition that PsA is a heterogeneous dis-
ease, most physicians apply the same ‘step up’ therapy to
all patients using single csDMARDs, then combinations of
these csDMARDs and then bDMARDs as patients fail to
respond to the previous treatment step [7, 9]. For this rea-
son, the tight control algorithm in the TICOPA trial used
this approach: first methotrexate, then combination
csDMARDs and then potentially escalating to bDMARDs.
For patients with mild disease, this may lead to overtreat-
ment and unnecessary side effects as they may not require
regular csDMARDs [10]. Although in the early Spondy-
loarthritis (SpA) study from Leeds, only 4 of 59 patients
had PsA, a previous study in undifferentiated peripheral
SpA found that 55% of patients did not require
csDMARDs and could be managed with only intra-
articular steroid injections and analgesia [10].
At the other end of the spectrum, patients with severe
disease may benefit from more aggressive early
intervention [11]. Both the Group for Research and
Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
and EULAR International treatment recommendations
utilise a ‘step up’ approach to treatment [7, 9] but suggest
more intensive therapy for those with poor prognostic
factors based on expert opinion. Applying initial intensive
therapy has shown improved outcomes in other
inflammatory arthritides such as RA [12] but has never
been tried in PsA. Combinations of DMARDs have shown
some superiority over single therapies in PsA [13] but the
data are limited. Early use of tumour necrosis factor
(TNF) inhibitors has also been shown to be superior to
methotrexate for patients with more severe disease [11,
14] but is more costly. If an early course of TNF inhibitors
can rapidly suppress inflammation allowing treatment to
be withdrawn and response maintained on methotrexate,
this may be a cost-effective model for early use.
Given this unmet need to address treatment strategy
in PsA within the T2T approach, the cohort has been
designed to support future pragmatic treatment studies.
Objectives {7}
The objective of the Multicentre Observational Initiative
in Treat to target Outcomes in Psoriatic Arthritis
(MONITOR-PsA) cohort is to assess clinical and
patient-reported outcomes, as well as costs associated
with a pragmatic routine implementation of a T2T ap-
proach, and compare those to the outcomes of the
TICOPA trial.
The MONITOR-PsA cohort also aims to facilitate re-
cruitment to a number of embedded trials (trials within
cohorts (TWiCs) design) to test alternative therapeutic
approaches in embedded clinical trials to provide an evi-
dence base for treatment strategy in PsA.
Trial design {8}
The MONITOR-PsA cohort establishes an inception co-
hort of PsA patients receiving a T2T treatment approach
within routine care. Given that this programme aims to
address outcomes with a pragmatic ‘T2T’ approach in a
real-life cohort and compare other therapeutic interven-
tions, the cohort utilises a Trials Within Cohorts
(TWiCs) design [15]. This design is particularly suited to
open label trials with ‘treatment as usual’ as the com-
parator. It is ideal for chronic conditions, situations
where multiple trials may be performed and where ex-
pensive desirable treatments are being trialled [15]. This
method recruits a central cohort having ‘treatment as
usual’ with regular observations and then adds pragmatic
trials of alternative therapies where a random group of
eligible patients are selected. This allows robust
generalizability from studies to routine health care,
avoids attrition and disappointment bias from controls
in open label studies as patients only receive information
relevant to their care, aids recruitment to trials, allows
routine collection of long-term outcomes and increases
efficiency with multiple trials within one cohort [15].
To date, one small feasibility study has used a TWiCs
design within a drug trial [16], but no large powered drug
trials have used this design. Initially, there were two
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interventional studies planned within the MONITOR-PsA
cohort but the hope is that this cohort will support mul-
tiple effectiveness trials comparing different approaches
with the standard ‘step-up’ care model that is most com-
monly used in routine practice in PsA. These can offer al-
ternative initial therapy at the time of diagnosis or can be
integrated at a defined time point in the treatment path-
way, for example, choosing a first biologic DMARD or
failing a first biologic DMARD. All of these studies would
offer interventional arms which will then be compared to
the standard step up approach used in the cohort. Patient
research partners have been involved in the study concept
and design from the beginning of the process. They sup-
ported the idea of utilising this new efficient study design
and have had significant input into the outcome measures
collected within the MONITOR-PsA cohort. Patient re-
search partners continue to advise on the management of
the cohort and the design of embedded trials.
Methods: participants, interventions and
outcomes
Study setting {9}
The MONITOR-PsA cohort is observational with imple-
mentation of a feasible treat to target approach, cur-
rently running within the rheumatology departments of
four secondary care hospitals in the UK.
Eligibility criteria {10}
Eligible participants will be as follows: willing and able to
give informed consent for the study; male or female; 18
years or over; have a clinical diagnosis of PsA confirmed
by the ClAsSification of Psoratic ARthritis (CASPAR)
criteria [17]; active PsA with ≥ 1 tender or swollen joints
or enthesis; not previously had treatment with DMARDs
for articular disease; and, in the investigators’ opinion, is
able and willing to comply with all study requirements.
All potentially eligible participants will be approached for
participation in the study by their treating rheumatology
team.
Female participants of child bearing potential and male
participants whose partner is of child bearing potential
must be willing to ensure that they or their partner use
effective contraception during potentially teratogenic
DMARD treatment and for 3months thereafter (or 2
years if received leflunomide unless treated with washout
therapy) as in standard practice. Women who are
pregnant, nursing or planning pregnancy during the
following 12months will only receive DMARDs that are
appropriate according to British Society of Rheumatology
(BSR) recommendations.
Participants may not enter the study if any of the
following apply: Current or previous treatment of arthritis
with synthetic DMARDs (including methotrexate,
leflunomide or sulfasalazine) or biologic DMARDs
(including TNF, IL12/23 or IL17 inhibitor therapies) or
targeted synthetic DMARDs (PDE4 of JAK inhibitor
therapies); or use of investigational therapies within 1
month or 5 biological half-lives of the baseline study visit
(whichever is longer).
Who will take informed consent? {26a}
Potential participants will be identified from new
referrals to the rheumatology service, particularly those
referred to the early arthritis clinic or dedicated PsA
clinic. Patients will be identified and approached initially
by their clinical care team and will be given brief
information about the study. If interested, a full patient
information sheet (PIS) and informed consent form
(ICF) will be given to them and explained. If they are
willing to participate in the observational study, consent
can be obtained on the same day. However, they will be
allowed as much time as they wish to consider their
participation. Written informed consent will then be
obtained by means of participant dated signature and
dated signature of the person who presented and
obtained the Informed Consent. The person who
obtained the consent must be suitably qualified and
experienced and have been authorised to do so by the
chief/principal investigator (CI/PI).
Given the TWiCs design which this cohort underpins,
the consent for the cohort includes an optional consent
to use participants’ personal details to contact them
about future research and explains that a random
selection of those eligible for an intervention arm of an
embedded treatment study (including clinical trials of
medicines) may be invited to participate in these
additional embedded studies. Participants are
randomised to the offer of an intervention but obviously
do not have to consent to participate in these. If
participants consent to being approached about further
research, they are made aware that their anonymised
data may be used as a ‘control arm’ to compare with
additional interventional studies.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
Additional, optional consent is sought from participants
for the collection of biological specimens including
blood, urine and stool samples. In addition, the consent
form asks for a participant’s consent to share their
anonymized data with other research groups.
Interventions
Explanation for the choice of comparators {6b}
The MONITOR-PsA cohort will receive ‘treatment as
usual’ with regular observations and then additional
pragmatic trials of alternative therapies can be
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implemented where a random group of eligible patients
are selected.
Intervention description {11a}
Within the cohort, patients will be assessed every 12
weeks during the first year of therapy and will be treated
in line with current standard step-up care. This will con-
sist of initial therapy with methotrexate alone, then al-
ternative DMARDs for non-response or intolerance,
then potentially biologic therapy following NICE recom-
mendations [2].
If an assessment is performed after 12 weeks on a new
therapy and participants have reached the target of
treatment, then this should be continued. If they have
not achieved minimal disease activity criteria (MDA) but
have shown significant improvement since starting the
new therapy (a reduction in tender and swollen joint
counts of at least 20%) then treatment should be
continued for a further 12 weeks before a repeat
assessment. If they have not responded significantly,
then the next step in the treatment protocol should be
offered. For biological and targeted synthetic DMARDs,
response must be recorded using the PsA Response
Criteria (PsARC) to fulfil NICE guidelines on the
prescriptions of these therapies. The timing of this
assessment varies by drug (TNF inhibitors 12 weeks,
apremilast and secukinumab 16 weeks, ustekinumab 24
weeks). If patients do not achieve a PsARC response,
then their treatment should not be continued. Providing
that new therapies can be tolerated by the patient and
do not cause significant toxicity, such that patients are
unwilling to continue with treatment or that treatment
must be stopped due to safety concerns, a trial of a
minimum of 12 weeks therapy should be given before
changing or adding an alternative DMARD.
Criteria for discontinuing or modifying allocated
interventions {11b}
The step-up treatment within the cohort is based around
assessment of the MDA criteria as these are a validated
and recommended target of treatment in PsA. If patients
do not achieve MDA by 24 weeks after initiating therapy
(or have not had an improvement of at least 20% in ac-
tive joint counts after 12 weeks on therapy), then treat-
ment should be escalated to the next step.
Strategies to improve adherence to interventions {11c}
This is an observational study embedded within usual
clinical practice. Hospital sites will employ their usual
strategies to improve adherence to treatment within the
cohort. These include counselling on disease-modifying
anti-rheumatic drugs by physicians, specialist nurses and
pharmacists, follow-up visits for counselling, adherence
and monitoring and written support materials given to
patients.
Relevant concomitant care permitted or prohibited
during the trial {11d}
As this is an observational cohort supporting pragmatic
trials, there are no prohibited concomitant care or
interventions within this study.
Provisions for post-trial care {30}
Within the MONITOR-PsA cohort, all medications
will be prescribed via usual care pathways and pa-
tients will be able to continue on their medications at
the end of the study as long as they are responding
well to treatment. For embedded trials, some medica-
tions may not be available beyond the end of the trial
period but that will be made clear to participants at
the time of consent to the embedded study and alter-
native therapies will be offered as appropriate in
standard rheumatology practice. At the end of any
embedded study period, participants return to usual
cohort follow-up allowing long-term assessment of
the impact of any tested interventions. Insurance is in
place via the sponsor and participating NHS sites for
any harm resulting from trial participation.
Outcomes {12}
The primary endpoint is the proportion of patients
achieving the PsA Disease Activity Score (PASDAS)
‘good’ response [18] at 48 weeks. The PASDAS is a
composite score including both clinical assessment and
patient-reported outcomes [19].
PASDAS responses are calculated as follows:
PASDAS calculation (((0.18 √ physician global VAS) + (0.159 √ patient
global VAS) – (0.253 x √ SF36 − physical component
summary score (PCS)) + (0.101 x LN (swollen joint
count + 1)) + (0.048 x LN (tender joint count +
1)) + (0.23 x LN (Leeds enthesitis index +
1)) + (0.37 LN (tender dactylitis count +
1)) + (0.102 x LN (C − reactive protein (CRP) + 1)) +
2) x 1.5.
Improvement
Final PASDAS score > 1.6 ≤ 1.6 but > 0.8 ≤ 0.8
≤ 3.2 Good Moderate Poor
> 3.2 but < 5.4 Moderate Moderate Poor
≥ 5.4 Moderate Poor Poor
The results will be discussed in the context of the
TICOPA trial [6] (n = 206) to see if they are
consistent. The patients recruited early in the course
of the study who therefore have longer-term follow-
up data will enable us to explore durability of the
response.
Key secondary endpoints include:
Rombach et al. Trials          (2021) 22:185 Page 5 of 14
 Time from baseline to first achieving MDA [20] and
PASDAS good response [18]
 Proportion achieving PASDAS good response [18] at
24 weeks
 Proportion achieving PASDAS moderate response
[18] at 24/48 weeks
 Healthcare costs and quality adjusted life years
(QALYs) (see below)
Exploratory outcomes (not available in TICOPA
dataset) will include:
 Change in PsA Impact of Disease (PsAID) score [21]
from baseline to 48 weeks
 Proportion achieving PsAID participant acceptable
symptom state (≤ 4) [21] at 48 weeks
 Change in work productivity (WPAI-SHP) [22]
(absenteeism, presenteeism and productivity loss) at
24 and 48 weeks
 Side effects reported at each time point, combined
with the Treatment Satisfaction Questionnaire for
Medication (TSQM)
 Outcomes at time points later than 48 weeks during
the longer-term follow-up of the cohort.
 Explore immune response in patients with PsA and
how this relates to clinical effectiveness with
standard therapies
All outcomes are collected via electronic case report
forms (eCRFs). Patient-reported outcomes are inputted
directly by the participants using a tablet computer, with
a paper version available in case completion on the tab-
let computer is not possible. A full list of outcome mea-
sures and their timings are provided in Table 1.
All adverse events will not be collected in this study as
all the medications used are currently used in PsA and
have well documented safety profiles. Only adverse
events of special interest (either extra-articular manifes-
tations of the disease or those likely to be related to the
therapy used for PsA) occurring during the study will be
collected at each study visit by patient questionnaire and
physician report as below:
 Patient reported: nausea/vomiting; heartburn/
dyspepsia; diarrhoea; fatigue; hair loss; and injection
site reactions
 Physician reported: infections; liver function test
abnormalities; neutropenia/leucopenia; and uveitis.
Serious adverse events that, in the opinion of the CI,
were ‘related’ (resulted from administration of any of the
research procedures) and ‘unexpected’ in relation to
those procedures will be reported.
Participant timeline {13}
Participants are recruited at or after the time of
diagnosis before they start on disease-modifying therapy.
Study visits in the cohort will be at 0, 12, 24, 36 and 48
weeks, every 6 months in year 2 and yearly thereafter in
line with routine practice to minimise burden and sup-
port retention of participants. In case of treatment escal-
ation at a later time point, visits will be repeated at 12,
24 and 48 weeks.
Different embedded trials can be included within this
approach either investigating initial treatment (with
participants randomised at the MONITOR-PsA baseline
visit) or at another specific treatment point in the
follow-up period, for example failure of a particular ther-
apy when subsequent treatment is investigated. Study
visits for embedded trials will be aligned with those for
the cohort wherever possible.
Sample size {14}
We aim to recruit a minimum of 500 participants to the
cohort, which may be extended if additional trials are
funded. No formal sample size calculations were
performed for the cohort. We estimate that around 200
participants will receive the standard treatment within
the cohort, which will allow for robust estimation of the
primary outcome, i.e. robust confidence intervals around
the proportion of participants receiving a PASDAS good
response at 48 weeks, to be compared to the outcomes
observed in the TICOPA trial [6].
Recruitment {15}
All patients newly diagnosed with psoriatic arthritis are
invited to join the cohort. The PIs at each site lead on
either psoriatic arthritis or early inflammatory arthritis
clinics allowing easy identification of the majority of
newly diagnosed patients. Initially, the study was
established with three sites, but this has been expanded
to improve recruitment rates with the addition of
further UK sites. To date, the majority of patients have
consented to join the study when invited with only a
small number of people declining most commonly
because of concerns about the duration of appointments
with additional questionnaires.
Assignment of interventions: allocation
Sequence generation {16a}
All patients entering into the MONITOR-PsA cohort
are registered using a centralised service run by the Ox-
ford Clinical Trials Research Unit (OCTRU). There is no
randomisation to different interventions as part of the
MONITOR-PsA cohort. Randomisation for any embed-
ded trials is undertaken via the same centralised service
(RRAMP) producing computer-generated randomised
allocations using a minimisation approach including a
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random element, which will ensure balanced allocations
across the treatment groups.
Concealment mechanism {16b}
No randomisations are performed as part of the
MONITOR-PsA cohort; as such no allocation conceal-
ment applies to this study. Embedded trials will random-
ise participants to their intervention with appropriate
allocation concealment. Details of these will be reported
in the protocols for the relevant trials.
Implementation {16c}
Participants will be registered in the MONITOR-PsA co-
hort using the central service (RRAMP) run by OCTRU.
If patients have consented in the MONITOR-PsA con-
sent form to be contacted about and randomised into
embedded studies, then they will be evaluated for inclu-
sion in any active trials at the appropriate treatment
time point. This is aided by a reminder within the cohort
database which identifies potentially eligible participants
and highlights this to the clinical team. Due to the
TWiCs design, randomisation occurs before all eligibility
criteria for embedded trials can be confirmed. This is be-
cause participants randomised to standard care will not
undergo further consent procedures and it allows some
trial specific procedures to be limited to the relevant
study arms (for example, screening for HIV and hepatitis
prior to the use of biologics). To allow this early ran-
domisation, with subsequent confirmation of eligibility,
we have implemented a two-stage randomisation process
outlined in Fig. 1.
If a participant is believed to be eligible for one of the
embedded trials, then the process of initial or first stage
randomisation will be performed by the study team
using the RRAMP system. Initial assessment of
inclusion/exclusion criteria that do not require blood
tests or other invasive assessments is performed by the
study team. If a patient appears to be eligible, they are
randomised and allocated to a treatment group. Patients
randomised to standard care do not receive any
additional information about the embedded study and
are given treatment as usual within the cohort.
Participants randomised to an intervention are then
given a specific patient information leaflet for the








Medical history X X X X X X X X
Medications X X X X X X X X
Physical examination X X X X X X X X
Routine blood tests (FBC, U&Es, LFTs, CRP and eGFR) X X X X X X X X
Immunology (RF, ACPA, ANA) X
Radiographs of hands/feet/spine X X X X
Eligibility assessment X
Adherence X X X X X X X
68/66 Joint count X X X X X X X X
Leeds and SPARCC enthesitis index X X X X X X X X
Dactylitis count X X X X X X X X
Psoriasis assessment (PASI and BSA) X X X X X X X X
Physician VAS X X X X X X X X
Metrology with BASMI (if axial involvement) X X X X
Patient questionnaires (VAS, HAQ, SF36, PsAID, WPAI,
BASDAI, BASFI)
X X X X X X X X
TSQM questionnaire X X X X X X X
EQ-5D-5L questionnaire X X X X X X
Healthcare utilisation data X X X X X
Adverse event assessments X X X X X X X X
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intervention they have been randomised to and invited
to join the study. If they decline, they are treated as
usual via the cohort. If they consent, further
investigations are performed as necessary for that
treatment arm and then a second stage randomisation is
completed allowing assessment of all inclusion and
exclusion criteria.
Assignment of interventions: blinding
Who will be blinded {17a}
Within the cohort, all participants receive open-label
treatment via usual care pathways. Within embedded tri-
als, treatment is usually open-label. To minimise bias
and ensure fair assessment of outcome measures, a
blinded assessor such as a study nurse performs the clin-
ical assessments at each study visit. To ensure that
blinding is maintained within the embedded trials, the
assessments are performed within the database in three
distinct sections, each with restricted with password
controls. Firstly, the participant completes their ques-
tionnaires, then the assessor enters a password to access
the clinical assessments, and finally the clinician enters a
separate password to enter information about side ef-
fects, drug prescriptions and health utilisation data. The
final screen summarises key outcomes including the
MDA, PASDAS score, BASDAI and PsAID to support
clinical decision making.
Procedure for unblinding if needed {17b}
Not applicable, as participants and treating clinicians are
not blinded to the intervention in this cohort study.
Data collection and management
Plans for assessment and collection of outcomes {18a}
The primary outcome, the PASDAS response, is a
composite score including patient-reported outcomes,
clinical assessments and a laboratory C-reactive protein
(CRP) value. All data entry is done directly into the clin-
ical database (OpenClinica) via tablet computers using
the study number as an identifier. Patient-reported out-
comes are also collected electronically wherever
possible.
Clinical assessments of disease activity are performed
by the blinded assessor who has undergone appropriate
training in the assessments required including joint
counts, enthesitis counts and Psoriasis Area and Severity
Index (PASI) scores. The GRAPPA training modules for
clinical assessments have been used to train new staff.
As with the questionnaires, these are inputted directly
into the study database via a tablet computer. All fields
must be completed on each page of the electronic CRFs
to minimise missing data and range checks are in place
for all numeric fields to promote data quality. As blood
tests are often not available until shortly after the
appointment, these can be entered later into the study
database, but an estimated PASDAS is calculated on the
day of the appointment using the most recent CRP
result.
The individual outcomes collected have been carefully
chosen to cover all of the new 2016 Outcome Measures
in Rheumatology (OMERACT) core and strongly
recommended domains for PsA studies [23]. All of these
outcomes have been validated in PsA and PASDAS was
chosen as the primary outcome as it encompasses
Fig. 1 Schematic of multi-stage consent process
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multiple domains of PsA [24]. A good response level
(reduction from baseline of ≥ 1.6 and final score of ≤
3.2) [18] has been chosen as this level of response is
desirable for physicians and patients [18]. This is
different to the TICOPA primary outcome but data are
available for comparison [6, 25].
Plans to promote participant retention and complete
follow-up {18b}
Study visits in the cohort are deliberately aligned to
usual clinical care. Given that most DMARD therapies
can take up to 12 weeks to work, assessment in early
arthritis is often at approximately 3-month intervals.
Once patients are stable, appointments are generally
gradually spaced out to minimise disruption to patients’
lives. Therefore, follow-up will be every 12 weeks in year
one, every 6 months in year 2 and annually thereafter. If
participants change therapy later in the course of their
disease, additional study visits will be performed at
weeks 12, 24 and 48 after any treatment change. This
will allow development of embedded trials testing alter-
native treatment strategies in more established disease.
Following the development of the COVID-19 pan-
demic in 2020, some remote follow-up had to take place
to ensure ongoing safety on treatment and subsequently
this was permitted (particularly at week 36) under a spe-
cific COVID-19-related amendment. The primary end-
point of the study requires physical assessments by a
clinician but during lockdown, limited information was
collected via remote follow-up when physician visits
were not possible.
As the cohort itself is non-interventional, participants
who withdraw will withdraw completely, including with-
drawal from follow-up. If they consent, their data up to
the point of withdrawal will be retained and utilised in
any analysis. Participants in embedded trials will be able
to withdraw from the intervention protocols but remain
in the cohort for follow-up.
Data management {19}
All information concerning the data management
procedures of the MONITOR-PsA cohort and embed-
ded studies are included in study specific data manage-
ment plans. Access to the study database is limited to
authorised personnel using individual log-ins. The study
database is stored on secure University of Oxford servers
with appropriate backup. In some other study sites, data
are collected using their local secure databases support-
ing existing database projects, before being transferred
securely to Oxford for amalgamation.
To ensure high-quality data, databases also include
multiple data validations, including checks for plausible
ranges, and valid date ranges. Additional data checks are
routinely performed by the study statistician. The
calculation of composite scores will be verified before
any analysis.
Confidentiality {27}
All data will be processed in compliance with applicable
data protection legislation, and all documents will be
stored safely in confidential conditions. On all study-
specific documents, other than the signed ICF and pa-
tient contact details, the participant will be referred to
by the study participant number/code, not by name.
Identifiable contact information will be stored separately
from study data and held at the local research site and
by the central coordinating team. For central monitoring
purposes, completed consent forms will be reviewed by
the coordinating trials unit, but these will be transferred
via secure data transfer to ensure personal details are se-
cure at all times.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
Routine safety and efficacy blood tests will be performed
for all patients receiving disease-modifying therapy as
done in standard NHS care, with samples handled ac-
cording to local practice. The results of the routine NHS
blood tests will be recorded to monitor safety of the
treatment, disease activity and for the study, to calculate
composite measures of efficacy. Participants consenting
to additional biological sampling will be asked to provide
up to 120 ml of blood at each study visit. This would be
taken at the same time as laboratory blood tests per-
formed in the clinic for safety and efficacy monitoring as
part of standard care.
Participants may also be asked to give samples of
urine and stool at these visits. Urine samples would be
collected in clinic, participants will provide stool
samples in their own home using containers provided
during their clinic visit and these can be delivered to the
sites at a visit or sent in the post. In some
circumstances, participants will also be asked to consent
to the collection of surplus samples of synovial fluid
where available. Synovial fluid samples would only be
taken at the time of arthrocentesis for diagnostic and
therapeutic reasons. Up to 100 ml is usually aspirated
from a large joint such as a knee, only 10mls of which is
used for diagnostic culture and microscopy, the
remainder being surplus to clinical requirements. If
synovial membrane were removed during diagnostic or
therapeutic arthroscopy, a small amount (less than 50%)
would be studied, once samples had been sent for
histology. This material would otherwise be discarded as
surplus to clinical requirements.
Serum and synovial fluid will be frozen for analysis of
constituents including proteins by enzyme-linked
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immunosorbent assay (ELISA), electrophoresis, mass
spectrometry and other biochemical assays. Mono-
nuclear cells will be obtained by density gradient centri-
fugation separation from blood and synovial fluid.
Immunophenotyping by flow cytometry will be carried
out at baseline and in-vitro assays will be performed.
The remainder of cells will be frozen for batched experi-
ments. DNA and RNA will be extracted for typing of
molecules of immunological importance including hu-
man leukocyte antigen typing and transcriptomic ana-
lysis. Stool and/or urine samples will be studied for
biomarkers including genetic and metabolomics analysis
of microorganisms potentially influencing the immune
system.
In the future, participants may be invited to participate
in subsequent ethically approved embedded clinical
trials based on phenotyping or genetic data obtained
through the biological sampling. These data will be held
in a pseudonymised form and used to assess eligibility
for future studies where a participant has consented to
this. The link to participant’s identifiable information
and contact details will be held by the study team and
used only where a participant has consented to be
contacted about future research. Any future contact
would come from this research team and would make
clear participants are under no obligation to participate
in any such study. Samples will be stored frozen in
secure research facilities for the duration of the study.
Samples will only be identifiable by the participant’s
study code.
Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
Analysis will be undertaken within OCTRU, supervised
by the statistician for the study and will be performed
after approximately 200 participants receiving the
standard treatment have been followed up for 48 weeks.
All analyses will focus on the participants not included
in any of the interventional arms of the embedded trials.
The primary endpoint is the proportion of patients
achieving the PASDAS ‘good’ response at 48 weeks, as
defined in {12}. The primary analysis will report the
outcomes together with 95% confidence intervals. The
estimates for the participants receiving the standard
treatment (pragmatic ‘step-up’ ‘treat to target’ treatment)
in MONITOR-PsA will be compared informally to the
outcomes for the relevant trial arms of the TICOPA trial
(i.e. no formal statistical tests will be performed).
Secondary endpoints of the MONITOR-PsA cohort
study will be presented descriptively for each follow-up
time point, including means with 95% confidence inter-
vals and/or medians with interquartile ranges and ranges
for continuous variables, proportions and corresponding
95% confidence intervals for binary outcomes.
Analyses of the participants recruited to the embedded
trials will be outlined in the separate protocols and
statistical analysis plans, and any deviations from the
plans will be justified and reported in the final report
and publications.
Interim analyses {21b}
No formal interim analyses are planned for the
MONITOR-PsA cohort ahead of the primary analysis.
The Data Safety and Monitoring Committee may see in-
terim descriptive summaries of accumulating data in
confidence.
Additional analyses of the longer-term follow-up are
planned to take place after the primary analysis of this
cohort. Subsets of the cohort including participants en-
rolled in the embedded trials may also be analysed
throughout the duration of the cohort.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
Supplementary analyses will be undertaken to explore
the many baseline prognostic factors in order to
examine which patients most benefit from this
treatment and whether important subgroups can be
defined. These analyses will be exploratory and utilise
descriptive summaries and logistic regression models.
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
Missing data will be minimised by careful study conduct
and data management. Missing data will be described
with reasons given where available; the number and
percentage of individuals in the missing category will be
presented.
The nature and mechanism for missing variables and
outcomes will be investigated, and if appropriate
multiple imputation will be used. Sensitivity analyses will
be undertaken assessing the underlying missing data
assumptions, if appropriate.
Economic analysis
An economic evaluation, in the form of a cost-
effectiveness analysis, is not planned as part of the
MONITOR PsA study. Instead, the analysis will be pre-
sented in a descriptive and informative way so as to es-
tablish comparisons in costs and QALYs estimates with
the predecessor of MONITOR, the TICOPA trial.
Data will be collected on the health resources used by
participants during the study period. At 24, 48 and 96
weeks post-randomisation participants and health pro-
fessionals will be asked to complete economic question-
naires in relation to hospital admission, medication,
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outpatient visits and community health care. Unit
cost data will be obtained from national databases
such as the BNF [26] and PSSRU costs of health and
social care [27].
Health Related Quality of life will be estimated using
the EuroQol EQ-5D 5 L for self-completion at baseline,
24, 48 and 96 weeks post-randomisation. As per the
NICE position statement, the responses to the EQ-5D-
5L will be converted into multi-attribute utility scores
using the approved ‘cross-walk’ to the 3 L instrument
using the mapping function developed by van Hout et al.
[28] and the converted responses will be valued using
the established time trade-off utility algorithm for the
UK [29]. QALYs will be calculated as the area under the
utility curve of utility scores from baseline, 24, 48 and
96 weeks, data using the trapezoidal rule [30].
The economic analysis will be conducted from a UK
NHS and Personal Social Services perspective (PSS)
using the cohort data.
Plans to give access to the full protocol, participant level-
data and statistical code {31c}
The full study protocol can be accessed by contacting
the trial team at MonitorPsA@ndorms.ox.ac.uk.
Anonymised participants level data and statistical codes
used for the analysis are available on request and subject
to data sharing agreements. Data sharing may only be
possible after relevant embedded trials have been
published.
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
This study will be conducted as part of the portfolio of
trials in the registered UKCRC Oxford Clinical Trials
Research Unit (OCTRU) at the University of Oxford. It
will follow their Standard Operating Procedures
ensuring compliance with the principles of Good
Clinical Practice and the Declaration of Helsinki and any
applicable regulatory requirements. The day-to-day
management of the study will be the responsibility of
the Clinical Trials Coordinator. This will be overseen by
the Study Management Group, who will meet monthly
to assess progress, as well as by OCTRU senior staff. It
will be the responsibility of the Clinical Trials Coordin-
ator and CI to undertake training of the research staff at
each of the study centres. The study statistician and
health economist will be closely involved in setting up
data capture systems, design of databases and clinical
reporting forms. A Trial Steering Committee (TSC) and
an Independent Data & Safety Monitoring Committee
(DSMC) have been established to cover this cohort study
and any embedded trials which includes patient research
partners.
The TSC, which includes independent members,
provides overall supervision of the study on behalf of the
funder. Its terms of reference have been agreed with the
funder and drawn up in a TSC charter which will
outline its roles and responsibilities. Meetings of the
TSC will take place at least once a year during the
recruitment period.
An outline of the remit of the TSC is to:
 Monitor and supervise the progress of the study
towards its interim and overall objectives,
 Review at regular intervals relevant information
from other sources,
 Consider the recommendations of the DSMC,
 Inform the funding body on the progress of the
study.
Composition of the data monitoring committee, its role
and reporting structure {21a}
The DSMC is a group of independent experts external
to the study who assess the progress, conduct,
participant safety and, if required critical endpoints of a
clinical trial. The DSMC has agreed and adopted an
appropriate charter that defines its terms of reference
and operation in relation to oversight of the study. They
will not be asked to perform any formal interim analyses
of effectiveness. They will, however, review accruing
data, summaries of the data presented by treatment
group, and will assess the screening algorithm against
the eligibility criteria. They will also consider emerging
evidence from other related research and review related
SAEs that have been reported. They may advise the
chair of the Trial Steering Committee at any time if, in
their view, the study (or embedded trial) should be
stopped for ethical reasons, including concerns about
participant safety. DSMC meetings will be held at least
annually during the recruitment phase of the study. Full
details including names will be included in the DSMC
charter. The TSC and DSMC for the study will also
cover any embedded trials within the cohort to allow
cohesive review of any safety issues.
Adverse event reporting and harms {22}
As the cohort supports clinical trials of investigational
medicinal products (IMPs), considerable thought has
been given to safety reporting. Within the cohort, only
serious adverse events (SAE) occurring to a participant
where in the opinion of the CI the event was ‘related’
(resulted from administration of any of the research
procedures) and ‘unexpected’ in relation to those
procedures will be reported. However, for participants in
the embedded trials, SAEs will be reported according to
the individual trial protocols.
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All non-serious adverse events will not be collected in
the cohort or current trials as all the IMPs are licenced,
currently used in PsA and have well documented safety
profiles. Only adverse events of special interest (either
extra-articular manifestations of the disease or those
likely to be related to the therapy used for PsA) occur-
ring during the study will be collected at each study visit
by patient questionnaire and physician report.
The following information will be recorded: severity,
assessment of relatedness to trial medication and action
taken. The severity of events will be assessed on the
following scale: 1 =mild, 2 =moderate, 3 = severe.
Follow-up information will be provided as necessary.
Frequency and plans for auditing trial conduct {23}
The study may be monitored, or audited in accordance
with the current approved protocol, Good Clinical
Practice (GCP), relevant regulations and standard
operating procedures. A Monitoring Plan will be
developed according to OCTRU’s standard operating
procedures (SOPs) which involves a risk assessment.
The monitoring activities are based on the outcome of
the risk assessment and may involve central monitoring
and on-site monitoring.
The study coordinator will be responsible for ensuring
adherence to the trial protocols at the trial sites. Quality
assurance checks will be undertaken by OCTRU to
ensure integrity of study entry procedures and data
collection. OCTRU has a quality assurance team who
will audit this study by conducting (at least once in the
lifetime of the study, more if deemed necessary) review
of the Trial Master File (TMF). Furthermore, the
processes of consenting, registration, provision of
information and provision of treatment will be
monitored. Written reports will be produced for the
TSC, informing them if any corrective action is required.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
Any significant amendments to the protocol will be
reviewed by the sponsor and the approving ethics
committee prior to any implementation. If any new
safety data becomes available, or there is a significant
change to the study design that would impact on
patients, then participants would be given an updated
patient information leaflet and where appropriate asked
to reconsent.
Dissemination plans {31a}
Trial results will be disseminated via scientific
publications and conference presentations. Results will
also be posted via the ClinicalTrials.gov website. With
assistance from the patient research partners, a lay
summary of the results will be developed for
dissemination to patients and the public. The
Investigators and research study team will be involved in
reviewing drafts of the manuscripts, abstracts, press
releases and any other publications arising from the
study. Authorship will be determined in accordance with
the ICMJE guidelines and other contributors will be
acknowledged. Authors will acknowledge that the study
was funded by the NIHR.
Discussion
The TICOPA trial has proven the benefits of a treat-to-
target approach but translation into clinical practice is
required to ensure that clinical care is optimised. The
lack of a feasible cost-effective model for this treat to
target approach has been an issue in widespread adop-
tion of the approach. The MONITOR-PsA cohort will
provide real world evidence of the effectiveness of a feas-
ible treat to target model with 3 monthly regular review.
All international treatment recommendations have
supported the treat to target concept but have
concluded that there is a lack of evidence to support
specific therapeutic choices in PsA. Within TICOPA all
of the patients were treated according to the same step
up protocol using DMARDs and then biologics. Given
the heterogeneous nature of the disease, it seems likely
that this approach could be optimised by personalising
therapeutic choices to the individual within the T2T
approach. When designing the study, the aim was to
provide a platform for testing of different forms of
personalised medicine in future studies including those
based on disease severity, a domain-based approach or a
focus on prognosis. For this reason the TWiCs study de-
sign was adopted.
Since the first publication on the cohort multiple RCT
or TWiCs trial in 2015, it has been adopted for a
number of studies in the last few years. However it
remains a relatively new study design. When developing
the study initially, we considered whether it would be
more appropriate to have one single unified protocol
covering the cohort and any embedded trials. The
sponsor’s office at the University of Oxford had no prior
experience of the TWiCS design but suggested using a
template allowing nested sub-studies. This would have
been efficient as outcomes and time points have to be
identical between the cohort and any trials. It would also
allow any amendments to be implemented within one
protocol. However, embedding trials as sub-studies of
the main cohort protocol would have meant that the tri-
als would never officially close given the single EudraCT
registration that would be provided under European reg-
ulations. Nearly all previous TWiCs studies have evalu-
ated other therapies such as physiotherapy and
radiotherapy rather than including interventional drug
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trials. Particularly with a drug trial, this would have
caused issues in the future as the trials cannot officially
be closed. For this reason, we chose to have separate
protocols for the cohort and the embedded studies,
allowing any embedded trials to be added and related to
the cohort, but then closed when they are complete. The
downside to this is that any change to the study design
necessitates amendments to multiple protocols with
multiple sponsor and ethics committees reviews with as-
sociated additional workload, delays and costs.
The inclusion of controlled trials of investigational
medicinal products presents specific challenges as
approval is required from the Medicines Health and
Regulatory Authority (MHRA) in the UK and they must
ensure that good clinical practice is followed. To our
knowledge, only one pilot TWiCs drug trial has been
established testing treatments for mesothelioma [16]. The
particular concern in this case is that participants are
randomised to different treatment arms of a drug trial
without any further consent after the cohort consent [31].
For that reason, input was sought from a specialist at the
MHRA despite the fact that the cohort itself is non-
interventional. The key is to ensure that the consent form
of this observational study would also satisfy requirements
for subsequent drug trials. Advice from the MHRA on
wording was invaluable in this regard.
The consent process required for this design also
mandated changes to the usual randomisation procedures.
Randomisation must be performed early in the process
prior to additional consent from participants. At this time
in the process, additional study specific procedures cannot
be performed to confirm all inclusion/exclusion criteria
until the randomisation arm is known. For this reason, the
randomisation has been split into two stages. The first
stage allows assessment of basic clinical inclusion criteria
and allows randomisation to one of the study arms.
Following a full baseline assessment, including trial
consent and baseline blood tests, the study team must
confirm the randomisation in a second stage to ensure
that all inclusion/exclusion criteria are met before
participants embark on study mandated treatment.
The use of a novel trial design in this cohort, has
identified challenges and required the study team to
actively engage stakeholders, such as the sponsor, the
MHRA and support teams within the clinical trials unit
with education, discussion and development of novel
solutions. However, solutions have been identified to
cover all of the key issues raised here and the cohort is
now successfully established in multiple sites in the UK.
We hope that in the long term, this cohort can supply
important insights into the natural history of early PsA,
whilst simultaneously supporting a number of embedded
pragmatic trials providing an evidence base of optimal
treatment approaches in routine clinical practice.
Trial status
The study is open for inclusion under protocol version
6, 28 July 2020. Recruitment started in April 2018 and
recruitment of the initial 500 patients will likely be
completed in 2023.
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